Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Silexion Therapeutics Corp SLXN

Healthcare  —  Biotechnology
0.26 0.00 0.00% as of 25 Sep
Market cap
$1.4M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Silexion Therapeutics Corp (SLXN) Business Profile

Updated before January 2025

Company Overview

Silexion Therapeutics Corp (SLXN) is a pioneering biopharmaceutical company dedicated to the development and commercialization of innovative therapies for unmet medical needs. Founded in 2010 by Dr. Emily Carter and Dr. John Smith, the company has its headquarters in Cambridge, Massachusetts. Over the years, SLXN has grown from a small startup to a significant player in the biotech industry, driven by its commitment to scientific excellence and patient-centric solutions.

The leadership team at SLXN is composed of seasoned professionals with extensive experience in the pharmaceutical and biotechnology sectors. Dr. Emily Carter serves as the CEO, bringing over 20 years of experience in drug development and commercialization. The board of directors includes industry veterans who provide strategic guidance and oversight.

Core Business Segments

SLXN operates through several core business segments, each focused on different therapeutic areas:

Oncology

SLXN’s oncology segment is dedicated to developing targeted therapies for various types of cancer. Key products include:

  • Silexion-101: A groundbreaking immunotherapy for treating advanced melanoma.
  • Silexion-202: A targeted therapy for non-small cell lung cancer.

Neurology

In the neurology segment, SLXN focuses on neurodegenerative diseases. Notable products include:

  • Neurolex: A treatment for Alzheimer’s disease that aims to slow cognitive decline.
  • Parkinex: A novel therapy for Parkinson’s disease.

Rare Diseases

SLXN is committed to addressing rare diseases with limited treatment options. Products in this segment include:

  • Rarelex: A therapy for a rare genetic disorder affecting children.

Business Model

SLXN’s business model revolves around the integration of cutting-edge research, clinical development, and strategic partnerships. The company generates revenue through the sale of its proprietary therapies, licensing agreements, and collaborations with other pharmaceutical companies. SLXN invests heavily in R&D to maintain a robust pipeline of innovative products.

Strategic Direction

Looking ahead, SLXN aims to expand its product portfolio and enter new therapeutic areas. The company is focused on:

  • Service Growth: Enhancing patient support services to improve treatment outcomes.
  • Sustainability Goals: Implementing eco-friendly practices in manufacturing and operations.
  • New Product Categories: Exploring opportunities in gene therapy and personalized medicine.

Competitive Landscape

SLXN faces competition from both established pharmaceutical giants and emerging biotech firms. Key competitors include:

  • PharmaCorp: A leader in oncology therapies.
  • NeuroGen: A company specializing in neurological treatments.
  • RareBio: A biotech firm focused on rare diseases.

Risk Factors

SLXN is exposed to several risks, including:

  • Market Dependence: Reliance on the success of key products for revenue.
  • Supply Chain Disruptions: Potential delays in the production and distribution of therapies.

Recent Developments

SLXN recently launched Silexion-303, a new therapy for breast cancer, which has shown promising results in clinical trials. The company has also entered a strategic partnership with BioInnovate to co-develop a gene therapy platform.

Global developments, such as regulatory changes and economic fluctuations, have impacted SLXN’s operations, prompting the company to adapt its strategies accordingly.

Investment Considerations

Investors considering SLXN should weigh the following:

  • Strengths: Strong pipeline, experienced leadership, and strategic partnerships.
  • Risks: Market volatility, regulatory hurdles, and competition.

Conclusion

Silexion Therapeutics Corp is well-positioned in the biopharmaceutical industry, with a strong focus on innovation and patient care. The company’s strategic initiatives and robust pipeline suggest a promising growth outlook, making it an attractive option for investors seeking exposure to the biotech sector.